Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorNalbanto?lu, Burçin
dc.contributor.authorDonma, Mustafa Metin
dc.contributor.authorÖzdilek, Burcu
dc.contributor.authorKarasu, Erkut
dc.contributor.authorNalbantoğlu, Ayşin
dc.date.accessioned2022-05-11T14:37:12Z
dc.date.available2022-05-11T14:37:12Z
dc.date.issued2013
dc.identifier.issn2008-2142
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8618
dc.description.abstractObjective: This study was designed to determine the current age-related hepatitis A virus (HAV) seroprevalance, vaccination status of children and to evaluate the epidemiological shift in HAV serostatus living in Tekirda?, which is located in Thrace region, the European part of Turkey. Methods: Children 6 months-12 years of age with simple health problems were included. Blood samples were studied for HAV IgM and IgG collectively. A questionnaire addressing several characteristics of subjects was administered to obtain basic descriptive data on HAV epidemiology. Vaccination status of the children was recorded according to the immunization cards. Findings: The overall anti-HAV IgM and anti-HAV IgG prevalance in children aged 6 months - 12 years was 3.3% and 25.4% respectively. Maximum hepatitis A IgM positivity was in the 7-12 years age group 4.8% (n= 12; P<0.001) and maximum hepatitis A IgG positivity in the same age group was 34% (n=85; P<0.001). HAV vaccination rate among patients aged more than 2 years was 11.03%. HAV IgG seroprevalance was higher in children of low monthly income families (36.1%, n=78; P<0.001) than in the intermediate (17%, n=31) and high income families (11.1%, n=6). Conclusion: These results indicate a shift in Hepatitis A seroprevalance when compared with the previous studies. As HAV infection in childhood is decreasing, the pool of susceptible adolescents and young adults is increasing. Introduction of hepatitis A vaccination into the national immunization schedule of Turkey should be considered. © 2013 by Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, All rights reserved.en_US
dc.language.isoengen_US
dc.publisherKowsar Medical Publishing Companyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitisen_US
dc.subjectHepatitis A Virusen_US
dc.subjectImmunizationen_US
dc.subjectVaccinationen_US
dc.subjecthepatitis A vaccineen_US
dc.subjectimmunoglobulin G antibodyen_US
dc.subjectimmunoglobulin M antibodyen_US
dc.subjectvirus antibodyen_US
dc.subjectage distributionen_US
dc.subjectarticleen_US
dc.subjectchilden_US
dc.subjectcontrolled studyen_US
dc.subjectfemaleen_US
dc.subjectgeographic distributionen_US
dc.subjecthepatitis Aen_US
dc.subjecthumanen_US
dc.subjectinfanten_US
dc.subjectlowest income groupen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmass immunizationen_US
dc.subjectonset ageen_US
dc.subjectpreschool childen_US
dc.subjectresidential areaen_US
dc.subjectschool childen_US
dc.subjectseroprevalenceen_US
dc.subjectTurkey (republic)en_US
dc.titleinfection and vaccination status of children aged 6 months-12 years: Time for mass vaccinationen_US
dc.typearticleen_US
dc.relation.ispartofIranian Journal of Pediatricsen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume23en_US
dc.identifier.issue3en_US
dc.identifier.startpage276en_US
dc.identifier.endpage280en_US
dc.institutionauthorNalbanto?lu, Burçin
dc.institutionauthorDonma, Mustafa Metin
dc.institutionauthorÖzdilek, Burcu
dc.institutionauthorKarasu, Erkut
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid36165893600
dc.authorscopusid6601976056
dc.authorscopusid55332319400
dc.authorscopusid55332236300
dc.authorscopusid54791156900
dc.identifier.scopus2-s2.0-84878666860en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster